NOTARZT 2004; 20(1): 3-9
DOI: 10.1055/s-2003-812602
© Georg Thieme Verlag Stuttgart · New York

Präklinische Notfalltherapie beim akuten Koronarsyndrom - Beschreibung eines aktuellen Standards nach EBM-Kriterien

Evidence-Based Prehospital Management of Acute Coronary SyndromesJ.  Koster1 , L.  Sinn1 , F.-J.  Neumann1
  • 1Herzzentrum Bad Krozingen (Ärztlicher Direktor: Prof. Dr. F.-J. Neumann), Bad Krozingen
Further Information

Publication History

Publication Date:
06 February 2004 (online)


Der akute Thoraxschmerz gehört zu den häufigsten Leitsymptomen im notärztlichen Rettungsdienst. Initiale Aufgabe des Notarztes ist es, einen Myokardinfarkt mit ST-Streckenhebung bereits präklinisch aus dem 12-Kanal-EKG zu diagnostizieren. Bei diesen Patienten müssen unverzüglich Reperfusionsmaßnahmen eingeleitet werden. Zahlreiche Studien haben gezeigt, dass die Reperfusion durch Katheterbehandlung der Fibrinolyse überlegen ist. Durch Transport des Patienten in ein Zentrum mit Katheterbereitschaft kann der Notarzt so entscheidende Weichen für eine effiziente Infarktbehandlung stellen. Die Katheterbehandlung ist auch dann der Fibrinolyse vor Ort überlegen, wenn sie einen erheblich längeren Transportweg bedingt. Die prähospitale Lyse ist mit Risiken verbunden, ohne dass ihr Nutzen im Rahmen der katheterbasierten Behandlungsstrategie gesichert wäre. Auch Therapiemaßnahmen wie die antithrombotische Therapie, inklusive der GP-IIb-IIIa-Rezeptorantagonisten und Thienopyridine sowie der Einsatz der β-Blocker und Analgetika werden anhand evidenzbasierter Kriterien besprochen.


Acute chest pain is one of the most frequent symptoms presenting to rescue service. Initial goal of the emergency physician is to diagnose myocardial infarction with ST-elevation preclinically with the use of a 12-lead-ECG. In these patients myocardial reperfusion strategies have to be instituted without delay. Numerous studies have shown that reperfusion by catheter intervention is superior to fibrinolysis. By transporting the patient to a centre with catheterisation facilities the emergency physician can set the stage for the most efficient treatment of myocardial infarction. Catheter intervention in acute myocardial infarction is superior to fibrinolysis even if this increases the distance for transport substantially. Prehospital thrombolysis is associated with risks without having shown benefit as part of a catheter-based reperfusion strategy. Other management strategies like therapy with antithrombotics - including GP IIb-IIIa receptor blockers or thienopyridines - analgetics and β-blockers will be discussed according to evidence-based criteria.


  • 1 Maroko P R, Radvany P, Braunwald E, Hale S L. Reduction of infarct size by oxygen inhalation following acute coronary occlusion.  Circulation. 1975;  52 360-368
  • 2 Madias J E, Hood W B. Reduction of precordial ST-segment elevation in patients with anterior myocardial infarction by oxygen breathing.  Circulation.. 1976;  53 (suppl I) 198-200
  • 3 Cannon C P, Braunwald E. Unstable Angina. In: Braunwald E Heart Disease 6th Edition. Philadelphia; WB Saunders Co 2001
  • 4 Hjalmarson A, Elmfeldt D, Herlitz J. et al . Effect on mortality of Metoprolol in acute myocardial infarction. A double-blind randomised trial.  Lancet. 1981;  2 823-827
  • 5 Teo K K. et al . Effects of prophylactic antiarrhythmic drug therapy in acute MI.  JAMA. 1993;  270 1589-1595
  • 6 First International Study of Infarct Survival Collaborative Group . Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1.  Lancet. 1986;  2 57-66
  • 7 Roberts R. et al . For the TIMI-IIB investigators. Immediate vs. deferred beta-blockade following thrombolytic therapy in patients with acute MI: results of TIMI-IIB.  Circulation. 1991;  82 422-437
  • 8 The MIAMI Trial Research Group . Metoprolol in acute myocardial infarction: patient population.  Am J Cardiol. 1985;  56 1G-57G
  • 9 Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials.  Prog Cardiovasc Dis. 1985;  27 335-371
  • 10 Deedwania P. Beta-Blockers and Cardiac Arrhythmias. New York, NY; Marcel Dekker Inc 1992
  • 11 Nademanee K, Taylor R D, Bailey W M. Management and long-term outcome of patients with electrical storm (abstract).  J Am Coll Cardiol. 1995;  25 187A
  • 12 ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction.  Lancet. 1995;  345 669-685
  • 13 Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico . GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction.  Lancet. 1994;  343 1115-1122
  • 14 Lewis H D. et al . VA Cooperative Study. Protective effects of aspirin against acute MI and death in men with unstable angina.  N Engl J Med. 1983;  309 396-403
  • 15 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group . Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2.  Lancet. 1988;  2 349-360
  • 16 Oler A. et al . Adding heparin to aspirin reduces the incidence of MI and deaths in patients with unstable angina: a meta-analysis.  JAMA. 1996;  276 811-815
  • 17 Ogilby J D, Kopelman H A, Klein L W, Agarwal J B. Adequate heparinization during PTCA: assessment using activated clotting times.  Cathet Cardiovasc Diagn. 1989;  18 206-209
  • 18 Narins C R, Hillegass W B, Nelson C L. et al . Relation between activated clotting time during angioplasty and abrupt closure.  Circulation. 1996;  93 667-671
  • 19 MacMahon S, Collins R, Knight C, Yusuf S, Peto R. Reduction in major morbidity and mortality by heparin in acute myocardial infarction (abstract).  Circulation. 1988;  78, (suppl II) II-98
  • 20 Wallentin L. et al . Efficacy and Safety of Tenecteplase in Combination with the Low-Molecular-Weight Heparin Enoxaparin or Unfractionated Heparin in the Prehospital Setting.  Circulation. 2003;  108 135-142
  • 21 The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) Investigators . Effects of Clopidogrel in addition to Aspirin in Patients with acute coronary Syndromes without ST-Segment Elevation.  N Engl J Med. 2001;  345 494-502
  • 22 Schömig A. et al . Intracoronary Stenting and Antithrombotic Regimen (ISAR). A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents.  N Engl J Med. 1996;  334 1084-1089
  • 23 Leon M B. et al . For the Stent Anticoagulation Restenosis Study (STARS) investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting.  N Engl J Med. 1998;  339 1665-1671
  • 24 Wallentin L, Lagerqvist B, Hsuted S. et al . For the FRISC II Investigators. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial.  Lancet. 2000;  356 9-16
  • 25 Cannon C P, Weintraub W S, Demopoulos L A. et al . Invasive versus conservative strategies in unstable angina and non-Q wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial: Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy: Thrombolysis in Myocardial Infarction.  Am J Cardiol. 1998;  82 731-736
  • 26 Fox K AA, Poole-Wilson P A, Henderson R A. et al . Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial.  The Lancet. 2002;  360 743-751
  • 27 The GUSTO investigators . An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.  N Engl J Med. 1993;  329 673-682
  • 28 Waever W D. et al . Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review.  JAMA. 1997;  278 2093-2098
  • 29 Keeley E C, Boura J A, Grines C L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomized trials.  Lancet. 2003;  361 13-20
  • 30 Andersen H R. et al, for the DANAMI-2 Investigators . A Comparison of Coronary Angioplasty with Fibrinolytic Therapy in Acute Myocardial Infarction.  N Engl J Med. 2003;  349 733-742
  • 31 Brahmajee K N, Bates E R. Percutaneous Coronary Intervention Versus Fibrinolytic Therapy in Acute Myocardial Infarction: Is Timing (Almost) Everything?.  Am J Cardiol. 2003;  92 824-826
  • 32 The TIMI IIIB Investigators . Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia.  Circulation. 1994;  89 1545-1556
  • 33 Bar F W. et al . Unstable Angina Study Using Eminase (UNASEM). Thrombolysis in patients with unstable angina improves the angiographic but not clinical outcome-results of UNASEM, a multicenter, randomised, placebo-controlled, clinical trial with Anistreplase.  Circulation. 1992;  86 131-137
  • 34 Gruppo Italiano per lo Studio della Streptochinase nell' Infarto miocardio (GISSI) . Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction.  Lancet. 1986;  1 397-402
  • 35 AIMS Trial Study Group . Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study.  Lancet. 1990;  335 427-431
  • 36 The European MI Project (EMIP) Group . Prehospital thrombolytic therapy in patients with suspected MI.  N Engl J Med. 1993;  329 383-389
  • 37 MITI Project Investigators . Influence of early prehospital thrombolysis on mortality and event-free survival (the Myocardial Infarction Triage and Intervention [MITI] Randomized Trial).  Am J Cardiol. 1996 Sep 1;  78 (5) 497-502
  • 38 Werf F van de, Ardissino D, Betriu A. et al . Management of acute myocardial infarction in patients presenting with ST-segment elevation.  Eur Heart J. 2003;  24 28-66
  • 39 Boersma E, Akkerhuis K M, Theroux P, Califf R M, Topol E J, Simoons M L. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.  Circulation. 1999;  100 2045-2048
  • 40 Montalescot G, Barragan T, Wittenberg O. et al (for the ADMIRAL Investigators) . Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.  N Engl J Med. 2001;  344 1895-1903
  • 41 Brenner S J. et al . Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. RAPPORT investigators. ReoPro And Primary PTCA Organization and Randomized Trial.  Am J Cardiol. 1999;  84 728-730
  • 42 Stone G W. et al, Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators . Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.  N Engl J Med. 2002;  346 957-966
  • 43 Neumann F J, Kastrati A. et al . Effect of Glycoprotein IIb/IIIa receptor blockade with Abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction.  J Am Coll Cardiol. 2000;  35 915-921
  • 44 Neumann F J, Blasini R, Schmitt C. et al . Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction.  Circulation. 1998;  98 2695-2701
  • 45 Schömig A, Kastrati A, Dirschinger J. et al for the Stent versus Thombolysis for Occluded coronary arteries in Patients with Acute Myocardial Infarction study investigators . Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction.  N Engl J Med. 2000;  343 385-391
  • 46 Kastrati A, Mehilli J, Dirschinger J. et al for the Stent versus Thrombolysis for Occluded coronary arteries in Patients with Acute Myocardial Infarction (STOPAMI-2) study . Myocardial salvage after coronary stenting plus Abciximab versus fibrinolysis plus Abciximab in patients with acute myocardial infarction: a randomised trial.  Lancet. 2002;  359 920-925
  • 47 Antmann E M. et al (For the TIMI-14 Investigators) . Abciximab facilitates the rate and extent of thrombolysis.  Circulation. 1999;  99 2720-2732
  • 48 Strategies for Patency Enhancement in the Emergency Department (SPEED) Group . Trial of Abciximab with and without low-dose reteplase for acute myocardial infarction.  Circulation. 2000;  101 2788-2794
  • 49 Brener S J, Adgey J A, Zeymer U. Combination of low-dose t-PA and eptifibatide for acute myocardial infarction - final results of the Intr-AMI study (abstract).  Circulation. 2000;  102 II-599
  • 50 The GUSTO V Investigators . Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.  Lancet. 2001;  357 1905-1914
  • 51 Sadowski Z P. et al . Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction.  Am Heart J. 1999;  137 792-798
  • 52 Waldo A L. et al for the Survival with Oral d-sotalol (SWORD) Investigators . Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote MI.  Lancet. 1996;  348 7-12
  • 53 The Cardiac Arrhythmia Suppression Trial (CAST) Investigators . Preliminary report: effect of encainide and flecainide on mortality in a randomised trial of arrhythmia suppression after myocardial infarction.  N Engl J Med. 1989;  321 406-412
  • 54 CAST II Investigators . Effect of the antiarrhythmic agent moricizine on survival after MI.  N Engl J Med. 1992;  327 227-233

Dr. med. Joachim Koster


Südring 15

79189 Bad Krozingen